Showing results (601-610 of 895) with videos related to
Sort By:
Pageof 90
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 19, 2005
Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung diseaseS Den Boon, E D Bateman, D A Enarson, et al.Journal of Contaminant Hydrology|September 1, 2024
Stream salinity prediction in data-scarce regions: Application of transfer learning and uncertainty quantificationKasra Khodkar, Ali Mirchi, Vahid Nourani, et al.The American Journal of Pathology|September 28, 2011
Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosisFlorian Rieder, Sean P Kessler, Gail A West, et al.International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|June 1, 1994
Changes in measurements of body fat distribution accompanying weight changeB Caan, M A Armstrong, J V Selby, et al.Royal Society Open Science|August 17, 2019
Mid-Devensian climate and landscape in England: new data from Finningley, South YorkshirePhilip I Buckland, Mark D Bateman, Ole Bennike, et al.Respiratory Medicine|September 1, 2016
Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysisRonald Dahl, Michael Engel, Daniel Dusser, et al.Respiratory Medicine|February 21, 2012
Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trialEric D Bateman, Eugene R Bleecker, Jan Lötvall, et al.Thorax|November 21, 2013
Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF aloneEric D Bateman, Paul M O'Byrne, William W Busse, et al.The Lancet. Respiratory Medicine|March 5, 2015
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsMario Castro, James Zangrilli, Michael E Wechsler, et al.Pulmonary Pharmacology & Therapeutics|April 12, 2015
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatmentIan P Hall, Andrew V Fowler, Abhya Gupta, et al.Pageof 90